Day: August 7, 2025

Second Quarter Highlights – 2025 vs. 2024Verification and certification revenue: $5.33M vs. $5.25M Product sales: $964,000 vs. $819,000 Total revenue: $6.6M vs. $6.4M Net income: $562,000 vs. $489,000 Diluted EPS: $0.11 vs. $0.09 Stock buybacks: 24,481 sharesSix Month Highlights – 2025 vs. 2024Verification and certification revenue: $9.5M vs. $9.7M Product sales: $1.7M vs. $1.6M Total revenue: $11.8M vs. $12.0M Net income: $593,000 vs. $667,000 Diluted EPS: $0.11 vs. $0.12 Cash generated from operations: $1.8M vs. $1.9M Cash & cash equivalents: $3.2M vs. $2.0M at 2024 year-end Stock buybacks: 55,826 shares Total buybacks since plan inception plus private purchases: 1,247,462 shares at purchase price of approximately $13.6 million $14.6M in total value returned to stockholders via buybacks, private purchases and a special dividend...

ATLANTA, Aug. 07, 2025 (GLOBE NEWSWIRE) — Cumulus Media Inc. (OTCQB: CMLS) (the “Company,” “Cumulus Media,” “we,” “us,” or “our”) today announced operating results for the three and six months ended June 30, 2025. Mary G. Berner, President and Chief Executive Officer of Cumulus Media, said, “While the advertising backdrop for legacy media remains challenging, in the quarter we continued to outperform our radio peers, gaining market share across all broadcast spot revenue channels. We also significantly outperformed in digital, delivering double the growth rate of our radio peers, driven by the 38% year-over-year increase in our digital marketing services business. Additionally, we executed $5 million of annualized cost reductions, bringing total annualized cost reductions...

— Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions based on current dataset — — Completed follow-on offering, raising $144.2 million in gross proceeds and extending cash runway into 2027 — — Secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to advance Prime Editors for Cystic Fibrosis — — Announced leadership transition and strategic restructuring: Allan Reine, M.D., named Chief Executive Officer; focusing efforts on advancing liver franchise and programs funded through external partnerships — CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company...

WILMINGTON, Del., Aug. 07, 2025 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for backup generators, gas pipelines and other critical infrastructure assets, announced results for its second quarter ended June 30, 2025 (Q2’25). Acorn will hold an investor call today at 11 a.m. ET (details below).Summary Financial Results($ in thousands) Q2’25 Q2’24 Change   6M’25 6M’24 ChangeMonitoring revenue $ 1,320     $ 1,110     +18.9%     $ 2,589     $ 2,212     +17.0%  Hardware revenue $ 2,205     $ 1,165     +89.3%     $ 4,034     $ 2,195     +83.8%  Total revenue(1) $ 3,525     $ 2,275     +54.9%     $ 6,623     $ 4,407     +50.3%  Gross margin   74.9%       73.2%     +170bps       75.0%       73.9%     +110bps  Net income to stockholders(2) $ 720     $ 271     +165.7%     $ 1,184     $ 336     +252.4%  Net...

Achieves Key Guidance Metrics Reaffirms 2024/2025 Two-Year Adjusted Free Cash Flow guidance TYSONS, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) — TEGNA Inc. (NYSE: TGNA) today announced financial results for the second quarter ended June 30, 2025. “We delivered on our financial commitments this quarter while making important progress on the strategic initiatives that will shape TEGNA’s future, including accelerating our technology roadmap and expanding our local news coverage by 100 hours a day,” said Mike Steib, CEO. “Our focus remains on reinventing how we operate and how we serve our audiences – by investing in local journalism, compelling content, and digital experiences.” “As we announced last year, our Chief Operating Officer, Lynn Beall is retiring on August 31, and I extend my sincere gratitude for her extraordinary leadership...

Outstanding Q4 Contributes to Record Year; Forecasting Growth in FY26 CLEVELAND, Aug. 07, 2025 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the quarter and fiscal year ended June 30, 2025, that included the following highlights (compared with the prior year period): Fiscal 2025 Fourth Quarter Highlights:Sales were a record $5.2 billion; organic sales growth was 2% Net income was $923 million, an increase of 18%, or $992 million adjusted, an increase of 12% EPS were $7.15, an increase of 19%, or a record $7.69 adjusted, an increase of 14% Segment operating margin was 23.9%, an increase of 170 bps, or 26.9% adjusted, an increase of 160 bps Repurchased $851 million of shares Announced agreement to acquire Curtis Instruments, Inc., expanding...

LOWELL, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal third quarter ended July 4, 2025. Third Quarter Fiscal Year 2025 GAAP ResultsRevenue was $252.1 million, an increase of 32.3%, compared to $190.5 million in the previous year fiscal third quarter and an increase of 6.9% compared to $235.9 million in the prior fiscal quarter; Gross margin was 55.3%, compared to 53.2% in the previous year fiscal third quarter and 55.2% in the prior fiscal quarter; Income from operations was $37.7 million, or 14.9% of revenue, compared to income from operations of $19.7 million, or 10.4% of revenue, in the previous year fiscal third quarter and income from operations of $34.9 million,...

– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2’25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase Program – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported...

INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025 Phase 1/2 data announced by Staidson BioPharmaceuticals for InflaRx-partnered C5a antibody BDB-001 in ANCA-associated vasculitis (AAV) were favorable, with Staidson expecting Phase 3 study initiation InflaRx working diligently toward unblinding of stopped Phase 3 pyoderma gangrenosum (PG) trial so that all data can be analyzed later this year Enrollment began in BARDA funded JUST BREATHE Phase 2 platform clinical trial investigating vilobelimab and additional novel therapeutic candidates for acute respiratory distress syndrome (ARDS) Cash, cash equivalents and marketable securities totaled €53.7 million on June 30, 2025 InflaRx estimates it has sufficient funds for currently planned operations...

Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBM Plan to meet with FDA regarding 1L NSCLC development path in 1H 2026, when PFS data becomes available Cash, cash equivalents, and investments of $142.8 million as of June 30, 2025; expected to be sufficient to fund operations into Q4 of 2027CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided...